Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04395937
Other study ID # B707202042981
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date September 1, 2023

Study information

Verified date November 2021
Source University of Liege
Contact Stephanie Ziant
Phone +3243668568
Email sziant@chuliege.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effects of regular exercise on asthma control has not yet been well demonstrated. The aim of this study is to investigate the impact of submaximal physical exercise on quality of life, on symptomatic control, and on bronchial and systemic inflammatory markers in patients with persistant asthma.


Description:

While it is well known that intense physical exercise can generate bronchospasm and limit exercise performance, it recently appeared that regular physical exercise practiced aerobically could improve the clinical status of asthmatic patients. The investigators are planning a 12-week randomized controlled study to assess the effect of regular aerobic exercise on quality of life, asthma control, bronchial hyperresponsiveness and bronchial and systemic inflammation in patients with persistent asthma The hypothesis is that regular physical exercise increases control and quality of life and reduces inflammation and bronchial hyperresponsiveness compared to simple physiotherapy sessions.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - asthmatic patient - aged 18- 90 years - ACQ > 1.5 - stable background treatment comprising at least one inhaled corticosteroid or an anti-leukotriene Exclusion Criteria: - IMC > 35 - severe osteoarthritis of the knees and hips - unstable angor - Severe uncontrolled hypertension

Study Design


Related Conditions & MeSH terms


Intervention

Other:
exercises
One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises

Locations

Country Name City State
Belgium Chu Liege Liège Liege

Sponsors (1)

Lead Sponsor Collaborator
University of Liege

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Asthma Quality of Life Questionnaire (AQLQ) A disease-specific health-related quality of life instrument that taps both physical and emotional impact of disease 32 items with 2-week recall, 4 different domains : Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items) 7-point Likert scale (7 = not impaired at all - 1 = severely impaired) Scores range 1-7, with higher scores indicating better quality of life. Change from Baseline AQLQ at 3 months 3 months
Primary Asthma Control Questionnaire (ACQ) A simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment.
7 items; 1 week recall (for items on symptoms and rescue inhaler use) ACQ has a multidimensional construct assessing symptoms (5 items--self-administered) and rescue bronchodilator use (1 item-self-administered), and FEV1% (1 item) completed by clinic staff 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use; and 7 categories for FEV1%) Scores range between 0 (totally controlled) and 6 (severely uncontrolled). Change from Baseline ACQ at 3 months
3 months
Primary FEV1 (Forced Expiratory volume in 1 second) Change from Baseline FEV1 at 3 months 3 months
Primary fall in FEV1 during ergospirometric measurement Change from Baseline fall in FEV1 during ergospirometric measurement 3 months
Primary Amount of eosinophils and neutrophils in sputum Change from baseline in amount of eosinophils and neutrophils in sputum 3 months
Primary FeNo (fractional exhaled nitric oxide) change from baseline FENO at 3 months 3 months
Primary PC20M (measures the concentration of metacholine necessary to bring down the FEV1 by 20% compared to its base value) Change from baseline PC20M at 3 months 3 months
Primary Vo2max (maximum oxygen consumption) change from baseline Vo2Max at 3 months 3 months
Primary PMA (Maximum aerobic power) change from baseline PMA at 3 months 3 months
Primary sputum cell counts change from baseline 3 months
Primary Hospital Anxiety and depression scale (HAD) The questionnaire comprises seven questions for anxiety and seven questions for depression For each item, 4 response modes coded from 0 to 3. The anxiety and depression items are alternating. In addition, an alteration in the order of the ratings was carried out to avoid biases linked to their repetition.
An overall score is calculated by adding the 14 items but also 2 subtotals corresponding to the 2 subscales. The higher the scores, the higher the symptomatology.
From 0 to 7 : absence of anxiety disorders and depressive disorders From 8 to 10 : anxiety and depressive disorders suspected From 11 to 21 : severe anxiety and depressive disorders
3 months
Primary Asthma control test (ACT) change from baseline A questionnaire to determine if patient's asthma symptoms are well controlled. A score varying between 1 and 5 is assigned to each question. A score varying between 1 and 5 is assigned to each question. The higher the total score, the better the asthma is controlled From 1 to 14 : Uncontrolled asthma From 15 to 19 : Partially Controlled Asthma From 20 to 25 : Well controlled asthma 3 months
Primary FVC (Forced Vital Capacity) FVC is the greatest total amount of air the patient can forcefully breathe out after breathing in as deeply as possible Change from Baseline FVC1 at 3 months 3 months
Primary TLC (Total Lung Capacity) It is the total volume of air in the lungs after a maximal inspiration change from baseline TLC at 3 months 3 months
Primary DLCO (Diffusing Capacity of the Lung for Carbon Monoxide) Measures the efficiency of the gas transfer characteristics of the lungs change from baseline DLCO at 3 months 3 months
Primary KCO (transfer coefficient of the lung for carbon monoxide) change from baseline KCO at 3 months 3 months
Primary FRC (Functional Residual Capacity) The volume of air present in the lungs at the end of passive expiration Change from baseline FRC at 3 months 3 months
Primary RV (Residual Volume) It is the amount of air remaining in the lungs after a maximal expiration Change from baseline RV at 3 months 3 months
Primary sGaw (Specific airway conductance) Change from baseline sGaw at 3 months 3 months
Primary maximal inspiratory power Measured in KPa Change from baseline 3 months
Primary maximal expiratory power Measured in KPa Change from baseline 3 months
Primary isometric force of long finger grasp measured using a Jamar dynamometer change from baseline 3 months
Primary maximum isometric force of the quadriceps measured using a dynamometer Change from baseline 3 months
Primary VOCs volatils organics compounds change form baseline 3 months
See also
  Status Clinical Trial Phase
Completed NCT01305369 - The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma Phase 4
Not yet recruiting NCT06457009 - Impact of Multi-Component Intervention on Suspected Asthma Population N/A
Completed NCT00739297 - The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388) Phase 1
Completed NCT02386722 - Intervention to Improve Inhalative Adherence N/A
Not yet recruiting NCT06163807 - Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry